BASEL, Switzerland,
June 18, 2018 /PRNewswire/ -- Myovant
Sciences (NYSE: MYOV), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative
therapies for women's health and endocrine diseases, today
announced that Lynn Seely, M.D.,
President and Chief Executive Officer of Myovant Sciences, will
present at the first annual Roivant Pipeline Day on
July 10, 2018 at 2:30 p.m. ET.
A live webcast will be available via the Events page under
the Investors and Media section of Myovant's website at
www.myovant.com. Please connect to the company's website at least
15 minutes prior to the presentation to ensure adequate time for
any software download that may be required to listen to the
webcast. A replay will also be available at the same location for
30 days following the conference.
About Roivant Pipeline Day
Roivant Pipeline Day will
be held on Tuesday, July 10, 2018 in
New York City. The event will
feature presentations, fireside chats, and Q&A sessions from
executives across the Roivant family of companies. The event is
scheduled to begin at 2:00 p.m. ET
and will continue until approximately 5:30
p.m. ET. Due to limited capacity, attendance is by
invitation only but a live webcast will be available to interested
parties. To request access to the webcast or to learn more about
the event, please email pipelineday@roivant.com.
About Myovant Sciences
Myovant Sciences is a
clinical-stage biopharmaceutical company focused on developing and
commercializing innovative therapies for the treatment of women's
health and endocrine diseases. Myovant's goal is to be the leading
global biopharmaceutical company focused on treating women's health
and endocrine diseases in areas of high unmet medical need.
Myovant's lead product candidate is relugolix, an oral, once-daily,
small molecule that acts as a GnRH receptor antagonist. Myovant has
initiated three clinical programs for relugolix consisting of five
international Phase 3 clinical trials, two in women with heavy
menstrual bleeding associated with uterine fibroids (LIBERTY 1 and
2), two in women with endometriosis-associated pain (SPIRIT 1 and
2), and one in men with advanced prostate cancer (HERO). Myovant is
also developing MVT-602, a kisspeptin agonist, for the treatment of
female infertility as part of assisted reproduction. Takeda
Pharmaceuticals International AG has granted Myovant an exclusive,
worldwide license to develop and commercialize relugolix (excluding
Japan and certain other Asian
countries where Takeda retains exclusive rights) and an exclusive
license to develop and commercialize MVT-602 in all countries
worldwide. Over time, Myovant intends to expand its development
pipeline to include other potential treatments for women's health
and endocrine diseases. For more information, please visit the
company's website at www.myovant.com.
Forward-Looking Statements
This press-release
contains forward-looking statements, including without limitation,
statements related to: Myovant's focus on developing and
commercializing innovative therapies for the treatment of women's
health and endocrine diseases, and Myovant's intention to expand
its development pipeline to include potential treatments for
women's health and endocrine diseases in addition to relugolix and
MVT-602. Forward-looking statements can be identified by the words
"anticipate," "believe," "can," "continue," "could," "estimate,"
"expect," "intend," "likely," "may," "might," "objective,"
"ongoing," "plan," "potential," "predict," "project," "should," "to
be," "will," "would," or the negative or plural of these words or
other similar expressions or variations, although not all
forward-looking statements contain these identifying words. Myovant
cannot assure you that the events and circumstances reflected in
the forward-looking statements will be achieved or occur and actual
results could differ materially from those expressed or implied by
these forward-looking statements. Forward-looking statements are
subject to a number of risks, uncertainties, assumptions and other
factors known and unknown that could cause actual results and the
timing of certain events to differ materially from future results
expressed or implied by the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those identified
herein, and those discussed in the section titled "Risk Factors"
set forth in Part I, Item 1A of Myovant's Annual Report on
Form 10-K which was filed with the Securities and Exchange
Commission on June 7, 2018, and other filings that Myovant
makes with the SEC from time to time. These statements are
inherently uncertain and investors are cautioned not to unduly rely
upon these statements. Except as required by law, Myovant
undertakes no obligation to update any forward-looking statements
to reflect events or circumstances after the date of such
statements.
Contact:
Media
Julie Normart
W2Opure
jnormart@w2ogroup.com
415.946.1087
View original content with
multimedia:http://www.prnewswire.com/news-releases/myovant-sciences-to-present-at-first-annual-roivant-pipeline-day-300667950.html
SOURCE Myovant Sciences